Biopharma · FDA Approvals · Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-assoc…
Assets on file: ARD-101
Dated catalysts for AARD, including recently decided ones.
Nothing scheduled in this window.
Every first-hand event for AARD, newest first.
Aardvark Reports Exploratory HERO/OLE Data for ARD-101 in PWS; Plans 2027 Phase 3
Aardvark released exploratory efficacy and safety data from its early-terminated Phase 3 HERO trial and OLE in hyperphagia associated with PWS. HQ-CT scores showed modest reduction by week 2 on ARD-101 with rebound off treatment; OLE switchers saw an additional 6-point drop. FDA lifted the clinical hold; the company plans to request an FDA meeting and resume PWS clinical activities in 2027 with a new lower-dose Phase 3 trial.
Aardvark Therapeutics: FDA lifts clinical hold on ARD-101 for Prader-Willi Syndrome
The FDA has lifted the clinical hold on the IND for ARD-101, allowing resumption of clinical development for hyperphagia in PWS. The company unblinded data from the terminated Phase 3 HERO trial and OLE and will host a webcast to review the exploratory dataset on October 23, 2026. Additional FDA alignment on Phase 3 trial design is anticipated prior to restarting.
Aardvark terminates Phase 3 HERO/OLE trials for ARD-101 in PWS
Company terminated both the Phase 3 HERO and OLE trials in June 2026 and does not intend to resume them as previously designed. FDA placed a full clinical hold on the ARD-101 IND in May 2026. Unblinded data from the terminated trials will be assessed in Q3 2026 to determine next steps.
Aardvark: FDA places full clinical hold on ARD-101 IND
FDA converted the company’s voluntary pause into a full clinical hold on the ARD-101 IND, halting both the Phase 3 HERO trial and the OLE trial. The company will unblind accumulated HERO and OLE data to evaluate efficacy and safety and to guide next steps with the agency.
Aardvark pauses Phase 3 HERO trial of ARD-101 in PWS
The company voluntarily paused enrollment and dosing in the Phase 3 HERO and OLE trials of ARD-101 after reversible cardiac observations in a healthy-volunteer study. It is working with the FDA to determine next steps and expects to provide further guidance in Q2 2026. ARD-201 development was also paused.
Aardvark pauses Phase 3 HERO/OLE and ARD-201 trials; guidance Q2 2026
Aardvark voluntarily paused enrollment and dosing in the Phase 3 HERO and OLE trials of ARD-101 for PWS hyperphagia and paused the ARD-201 obesity program after reversible QRS prolongation signals were seen in healthy-volunteer cardiac-safety studies. The company is reviewing data with the FDA and will provide further guidance on both programs in Q2 2026.
Companies in the same sector closest to AARD in market value.